JHL Biotech, Inc, a Taiwan-based bio-pharmaceutical firm, completed a $45.6 million series C Round of financing that was led by an anonymous investor, according to the company’s statement.
The main investor is a global crossover fund that has over $1.6 trillion in assets-under-management.
Existing investor Milestone Capital, as well as new investors Sungent BioVenture and Liwick Investment Management, also participated in the round.
The company says it plans to use the latest proceeds toward continuing its clinical trials, construction of a fill-finish facility in its Wuhan plant, expanding its pre-clinical novel therapeutic portfolio, as well as working capital.
"As we prepare to file for a listing on the Taiwan Emerging Stock Market, closing this round of financing validates our position in the market, and provides us with the capital needed to push through to the next phase of our product development," says Racho Jordanov, president and CEO of JHL Biotech.